Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Nature

27 novembre 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Herbst RS,Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Nature Medicine

20 novembre 2014
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G,Zitvogel L.

Nivolumab in Previously Untreated Melanoma without BRAF Mutation.

New England Journal of Medicine

16 novembre 2014
Nivolumab in Previously Untreated Melanoma without BRAF Mutation.

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA.

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)

Lancet Oncology

7 février 2014
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer a multicentre, prospective trial (SAFIR01/UNICANCER).

André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, Adélaide J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonneterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H.

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib.

New England Journal of Medicine

16 novembre 2014
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.

 

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Nature

4 septembre 2014
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S.

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

Science

22 novembre 2013
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide